PTK2 and non-small cell lung carcinoma: Thus, our results have identified a promising drug combination strategy targeting EGFR and FAK in NSCLC, and indicate that a treatment regimen including a FAK inhibitor may prove more beneficial than treatment with erlotinib alone in patients harboring inherent EGFR TKI-resistant NSCLC.